Skip to content

Role of Bromocriptine in patients with difficulty in speech following stroke

Effectiveness of Bromocriptine in non-fluent aphasia after stroke.

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/04/003539
Enrollment
88
Registered
2013-04-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Stroke patients with aphasia

Interventions

Intervention1: Bromocriptine : 2.5mg four times daily for 4 months orally Control Intervention1: Speech therapy: 8-10 hrs per week for 4 months

Sponsors

Dr Reeba Sini Jacob
Lead Sponsor
Dr M Jayasree
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: a) 18 years of age and above b) CT/MRI confirmed diagnosis of Right, Left or bilateral hemispheric thrombotic infarct c) With premorbid ability to read and write d) Within 6 months of onset of nonfluent aphasia

Exclusion criteria

Exclusion criteria: a) Any patient with hearing, visual impairment or both b) History of malignancy c) Evidence of severe cardiac, hepatic, renal, pulmonary or other chronic or neuropsychiatric disorder, as determined by history, physical examination, and screening laboratory tests. d) Those unwilling to participate in the study

Design outcomes

Primary

MeasureTime frame
verbal fluency, comprehension, repetition and naming using the Western Aphasia BatteryTimepoint: 0 and 16 weeks

Secondary

MeasureTime frame
Patients are assessed with speech evaluation by noting changes in verbal fluency, comprehension, repetition and naming using the Western Aphasia Battery.Timepoint: 0, 8, 16 and 24 weeks

Countries

India

Contacts

Public ContactReeba Sini Jacob

Government Medical College, Thiruvananthapuram

jayasreem3@gmail.com09447131413

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026